CTLA4 and melanoma: Currently, CTLA-4 inhibitor Ipilimumab has been approved by FDA for the adjuvant treatment of stage III melanoma and the treatment of advanced melanoma [121], and clinical studies of Ipilimumab and Telimomab in kidney cancer, prostate cancer and lung cancer have been widely carried out.